01 / 05
Scientists Think It Possible to Protect Aging Brains with Lithium

CNN | Noncommunicable Disease

Scientists Think It Possible to Protect Aging Brains with Lithium

“Lithium is best known to medicine as a mood stabilizer given to people who have bipolar disorder and depression. It was approved by the US Food and Drug Administration in 1970, but it was used by doctors to treat mood disorders for nearly a century beforehand.

Now, for the first time, researchers have shown that lithium is naturally present in the body in tiny amounts and that cells require it to function normally — much like vitamin C or iron. It also appears to play a critical role in maintaining brain health.

In a series of experiments reported Wednesday in the journal Nature, researchers at Harvard and Rush universities found that depleting lithium in the diet of normal mice caused their brains to develop inflammation and changes associated with accelerated aging.

In mice that were specially bred to develop the same kinds of brain changes as humans with Alzheimer’s disease, a low-lithium diet revved the buildup of sticky proteins that form plaques and tangles in the brains that are hallmarks of the disease. It also sped up memory loss.

Maintaining normal lithium levels in mice as they aged, however, protected them from brain changes associated with Alzheimer’s.

If further research supports the findings, it could open the door to new treatments and diagnostic tests for Alzheimer’s, which affects an estimated 6.7 million older adults in the United States, according to the US Centers for Disease Control and Prevention.”

From CNN.

Medical Xpress | Noncommunicable Disease

GLP-1 Drug Linked to Heart Benefits for High-Risk Patients

“Adding the GLP-1 receptor agonist drug tirzepatide (marketed as Mounjaro) to standard care for patients with type 2 diabetes and heart disease is associated with a lower risk of a major cardiovascular event, such as a heart attack or stroke, finds a study published by The BMJ today…

A total of 52,971 individuals were included in the analysis (average age 70 years; 51% female), of whom 35,353 started tirzepatide and 17,618 started sitagliptin.

At one year, the risk of MACE was 2.9% in the tirzepatide group and 4.4% in the sitagliptin group (a 32% relative reduction), and the researchers estimate that for every 70 patients starting tirzepatide, one case of MACE would be prevented.

For individual MACE components, tirzepatide was associated with a 33% lower risk of heart attack compared with sitagliptin, whereas ischemic stroke showed no meaningful difference.”

From Medical Xpress.

Fierce Pharma | Noncommunicable Disease

Gilead, Merck’s Phase 3 Data Back First Weekly HIV Pill

“Detailed phase 3 results suggest the two-drug combination of Gilead Sciences’ lenacapavir and Merck & Co.’s islatravir has what it takes to become the first complete weekly pill for the treatment of HIV.

Two Islend clinical trials confirmed that a once-weekly, single-tablet combination of islatravir and lenacapavir (ISL/LEN) matches daily treatments like Gilead’s Biktarvy at maintaining HIV viral suppression, according to data slated for presentation at the 26th International AIDS Conference in Rio de Janeiro, Brazil.”

From Fierce Pharma.

ScienceDaily | Noncommunicable Disease

Cancer-Fighting Chewing Gum Drastically Cuts HPV Levels

“Researchers have developed a bioengineered chewing gum that may offer a new way to target microbes associated with head and neck cancer. In tests involving oral samples from patients, extracts from the gum sharply reduced one virus and two types of bacteria linked to the disease…

Tests showed that extracts from the bean gum lowered HPV levels by 93% in saliva samples. HPV levels also fell by 80% in oral rinse samples.

The researchers then engineered the bean gum to contain protegrin, an antimicrobial peptide capable of killing harmful bacteria. A single dose brought levels of Pg and Fn down to almost zero.

Importantly, the treatment did not appear to harm the beneficial bacteria that normally live in the mouth.”

From ScienceDaily.

TVC News | Communicable Disease

Nigeria’s Malaria Prevalence Falls from 42 Percent to 15 Percent

“Highlighting progress made in malaria control, the minister revealed that findings from the 2025 Nigeria Malaria Indicator Survey showed malaria prevalence had fallen from 42 per cent in 2010 to 15 per cent in 2025.

He, however, noted that Nigeria still accounts for 24.3 per cent of global malaria cases and 30.3 per cent of malaria-related deaths, stressing the need to intensify efforts to eliminate the disease.”

From TVC News.